Essential Partners
MAZE icon

Essential Partners’s Maze Therapeutics MAZE Stock Holding History

Essential Partners’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$190 Hold
7
– – ﹤0.01% 2607
2026
Q2 		$209 Hold
7
– – ﹤0.01% 2630
2026
Q1 		$209 Hold
7
– – ﹤0.01% 2601
2025
Q4 		$290 Hold
7
– – ﹤0.01% 2348
2025
Q3 		$182 Hold
7
– – ﹤0.01% 2413
2025
Q2 		$86 Buy
+7
New +$73 ﹤0.01% 2088

Other funds holding MAZE

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners's MAZE Position: Q3 2026 in Review

Essential Partners held its Maze Therapeutics (MAZE) position steady in Q3 2026 at 7 shares worth $190. The position accounts for ﹤0.01% of the portfolio, ranked #2607.

Essential Partners first reported a position in MAZE in Q2 2025 and has held it in 6 quarters since. The position peaked at $290 in Q4 2025. 9 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Essential Partners held 7 shares of Maze Therapeutics worth $190 as of Q3 2026.
  • Essential Partners left its Maze Therapeutics share count unchanged in Q3 2026.
  • Maze Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2607 holding.
  • Essential Partners first reported a position in Maze Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Maze Therapeutics position peaked at $290 in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.